Eculizumab (Soliris)
A complement-blocking biologic FDA-approved for AQP4-IgG-positive NMOSD; carries an FDA Boxed Warning for meningococcal infection and requires vaccination before treatment.
Drug Class: Biologics
Eculizumab (Soliris) is a monoclonal antibody that blocks complement protein C5, part of the immune system. It is FDA-approved to prevent relapses in adults with AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD). It is given as an IV infusion through a REMS program because of a serious infection risk.
Official website: solirisnmosd.com
Key Takeaways
- FDA-approved for AQP4-IgG-positive NMOSD (the antibody-positive form)
- FDA Boxed Warning: life-threatening meningococcal infection - vaccination is required before the first dose
- Highly effective at preventing relapses, but does not reverse damage already done
- Long-term IV infusion through a REMS-restricted program
- Other FDA-approved options exist - ravulizumab, inebilizumab, and satralizumab may be preferred in selected patients
FDA Boxed Warning - Meningococcal infection
Eculizumab blocks part of the complement system that defends against Neisseria bacteria. Cases of life-threatening meningococcal meningitis and sepsis have occurred, including in vaccinated patients. To reduce this risk:
- Both MenACWY and MenB vaccines must be given at least 2 weeks before the first dose. If treatment can't be delayed, vaccinate as soon as possible and use prophylactic antibiotics until 2 weeks after vaccination.
- Some clinicians also prescribe daily oral antibiotics (such as penicillin V), especially when treatment starts before vaccination protection is complete or when local practice favors additional prophylaxis.
- You will be enrolled in the Soliris REMS program and given a Patient Safety Card to carry at all times.
- Call 911 immediately or go to the emergency department for fever, headache, stiff neck, confusion, light sensitivity, rash, nausea/vomiting, or severe muscle aches - these can be signs of meningococcal infection and can progress quickly even after vaccination.
How It Works
Eculizumab binds to complement protein C5 and stops it from being cleaved into C5a and C5b. This blocks formation of the membrane attack complex, which contributes to optic nerve and spinal cord damage in NMOSD.
Use in NMOSD
- For AQP4-IgG-positive NMOSD (it has not been studied for MOGAD or AQP4-negative NMOSD)
- Prevents future attacks - it does not reverse damage that has already occurred
- The PREVENT trial showed a ~94% relative reduction in relapse risk compared with placebo
Administration
The label dosing for adult AQP4-IgG-positive NMOSD is:
- Induction: 900 mg IV once weekly for the first 4 weeks
- Week 5: 1,200 mg IV
- Maintenance: 1,200 mg IV every 2 weeks thereafter
- Each infusion takes about 35 minutes
- Generally a long-term relapse-prevention treatment; duration is individualized
Specific dosing decisions are made by your prescriber. Tell your team about any planned vaccinations or surgical procedures, since infection risk is the central safety concern.
Side Effects
Most common in clinical trials:
- Upper respiratory tract infection
- Headache
- Back pain, joint pain, muscle aches
- Nausea
- Infusion reactions
Serious but less common:
- Meningococcal and other encapsulated-organism infections (see boxed warning above)
- Serious systemic infections (sepsis, gonorrhea, Haemophilus influenzae)
- Hypertension
Monitoring
- Symptoms of infection at every visit and between visits
- Vaccination status (boosters per CDC guidance)
- NMOSD relapse symptoms (vision loss, weakness, sensory changes)
- Routine labs as directed by your prescriber
Pregnancy and Lactation
Eculizumab is a large IgG antibody; placental transfer increases in the third trimester. Limited human data suggest no clear pattern of birth defects, but the medication should be used during pregnancy only if benefit outweighs risk. Discuss vaccination of the newborn and breastfeeding plans with your team well in advance.
Cost and Access
Eculizumab is among the most expensive medications in the United States. Coverage varies; manufacturer patient-assistance and copay programs exist. Some stable patients transition to ravulizumab (Ultomiris), a longer-acting C5 inhibitor with an every-8-weeks maintenance schedule. Inebilizumab (Uplizna) and satralizumab (Enspryng) are also FDA-approved NMOSD biologics with different mechanisms; the right choice depends on antibody status, prior treatments, and other factors.
Frequently Asked Questions
Why do I need vaccinations before starting?
Blocking complement leaves the body more vulnerable to encapsulated bacteria - especially Neisseria meningitidis. Vaccinating at least 2 weeks before the first infusion gives your immune system time to mount protection. Even with vaccination, prompt evaluation of any febrile illness is essential.
Will it reverse the vision or strength I've already lost?
No. Eculizumab is a relapse-prevention drug, not a recovery drug. Recovery from a past attack depends on the original injury and rehabilitation. The point of treatment is to prevent the next attack.
Can I switch to ravulizumab?
Some patients do, because ravulizumab is dosed every 8 weeks rather than every 2. Switching is a discussion with your neurologist and depends on disease stability, insurance, and personal preference.
References
- U.S. Food & Drug Administration. Soliris (eculizumab) Prescribing Information.
- Pittock SJ, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614-625.
- Soliris REMS Program. solirisrems.com.
Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice. Eculizumab is dispensed only through a restricted REMS program; all dosing and monitoring decisions are made by your prescribing clinician.